Lithium batteries power an expanding range of technologies, from electric vehicles and commercial transportation fleets to stationary energy storage systems and grid-scale backup power installations.

GenerMotor is a pioneer in high-voltage DC (HVDC) power solutions, specializing in modular, stackable power generation technology designed for the AI and data center era. Collaborating with industry ...

Recent developments in the biopharma AI world include an alliance between Thermo and Datavant, plus news from Insilico, Evinova, BPGbio, Evogene, and AMPLY.

BorgWarner's battery management system (BMS) has been selected for an expanded series-production program with a global original equipment manufacturer (OEM). BorgWarner has supplied the BMS to the ...

Bristol Myers Squibb (BMS) is confident pivotal readouts from its core pipeline will drive profits towards 2030 despite looming patent expiries for revenue leaders Opdivo and Eliquis, says CEO ...

Bristol Myers Squibb (BMS) has agreed as part of a deal with the US government to provide Eliquis (apixaban) free of charge to Medicaid. The company has also agreed to donate more than seven tons of ...

PXI/PXIe solution offers scalable, modular design for faster development cycles and lower total cost of ownership, plus improved safety Pickering Interfaces, the leading supplier of modular signal ...

Add Silicon Canals to your Google News feed. PXI/PXIe solution offers scalable, modular design for faster development cycles and lower total cost of ownership, plus improved safety CLACTON-ON-SEA, ...

Bristol Myers Squibb is spinning off a fresh company armed with five autoimmune disease drugs and $300 million in Bain Capital-led financing as part of the Big Pharma’s ambitious cost-cutting drive.

Bristol Myers Squibb (BMS) has announced it will buy the oncology drug developer Mirati Therapeutics, setting it up to gain Krazati (adagrasib), a KRAS inhibitor that received approval from the US ...

Bristol Myers Squibb, Board Chair of BMS and CEO Christopher Boerner, PhD, have committed the pharma giant to investing $40 billion over the next five years toward U.S. research and development (R&D), ...